Baseline characteristics of all patients
| Characteristics . | Without statin (N = 76) . | With statin (N = 53) . | P value . |
|---|---|---|---|
| Age, y | 60.4 (51.8-68.7) | 66.9 (57.7-71.9) | .05 |
| Sex, male | 36 (47.4) | 28 (52.8) | .594 |
| MPN subtype | |||
| ET | 23 (30.3) | 20 (37.7) | .687 |
| PV | 43 (56.6) | 25 (47.2) | |
| Prefibrotic myelofibrosis | 5 (6.6) | 5 (9.4) | |
| Primary myelofibrosis | 5 (6.6) | 3 (5.7) | |
| Driver mutation | |||
| JAK2V617F | 57 (75.0) | 44 (83.0) | .765 |
| CALR | 13 (17.2) | 5 (9.4) | |
| MPL | 3 (3.9) | 1 (1.9) | |
| Triple negative | 3 (3.9) | 3 (5.7) | |
| Follow-up time, y | 4.6 (2.2-6.5) | 4.9 (2.3-6.8) | .610 |
| Smoking status | |||
| Never | 49 (64.5) | 24 (45.3) | .041 |
| Former | 15 (19.7) | 21 (39.6) | |
| Current | 12 (15.8) | 8 (15.1) | |
| Alcohol, units per week | |||
| ≤10 | 34 (44.7) | 23 (43.4) | .795 |
| >10 | 11 (14.5) | 9 (17.0) | |
| Missing | 31 (40.8) | 21 (39.6) | |
| BMI, kg/m2 | 24.8 (22.6-27.4) | 25.3 (22.3-28.0) | .843 |
| Comorbidities | |||
| Hypertension∗ | 25 (32.9) | 38 (71.7) | <.001 |
| Type 2 diabetes | 3 (4) | 10 (18.9) | .007 |
| Thromboembolic event† | 19 (25) | 27 (50.9) | .003 |
| Statin treatment | |||
| Moderate intensity‡ | 33 (62.3) | <.001 | |
| High intensity§ | 20 (37.7) | ||
| Cytoreductive treatment | |||
| HU | 23 (30.3) | 23 (43.4) | .139 |
| Pegylated IFN-α2 | 53 (69.7) | 30 (56.6) | |
| Laboratory test | |||
| Hemoglobin, g/dL | 16.0 (14.2-18.5) | 15.3 (13.7-17.2) | .229 |
| Erythrocytes, ×1012/L | 5.6 (4.8-6.8) | 5.2 (4.6-6.0) | .074 |
| WBC, ×109/L | 9.8 (7.5-10.5) | 10.1 (8.2-12.8) | .521 |
| Platelets, ×109/L | 680 (451-888) | 596 (516-753) | .405 |
| JAK2V617F, % | 34.0 (11.8-46.8) | 34.1 (18.0-49.5) | .719 |
| Total cholesterol, mmol/L | 4.9 (4.4-5.7) | 4.0 (3.4-4.5) | <.001 |
| LDL-C, mmol/L | 2.9 (2.4-3.3) | 1.8 (1.6-2.3) | <.001 |
| Characteristics . | Without statin (N = 76) . | With statin (N = 53) . | P value . |
|---|---|---|---|
| Age, y | 60.4 (51.8-68.7) | 66.9 (57.7-71.9) | .05 |
| Sex, male | 36 (47.4) | 28 (52.8) | .594 |
| MPN subtype | |||
| ET | 23 (30.3) | 20 (37.7) | .687 |
| PV | 43 (56.6) | 25 (47.2) | |
| Prefibrotic myelofibrosis | 5 (6.6) | 5 (9.4) | |
| Primary myelofibrosis | 5 (6.6) | 3 (5.7) | |
| Driver mutation | |||
| JAK2V617F | 57 (75.0) | 44 (83.0) | .765 |
| CALR | 13 (17.2) | 5 (9.4) | |
| MPL | 3 (3.9) | 1 (1.9) | |
| Triple negative | 3 (3.9) | 3 (5.7) | |
| Follow-up time, y | 4.6 (2.2-6.5) | 4.9 (2.3-6.8) | .610 |
| Smoking status | |||
| Never | 49 (64.5) | 24 (45.3) | .041 |
| Former | 15 (19.7) | 21 (39.6) | |
| Current | 12 (15.8) | 8 (15.1) | |
| Alcohol, units per week | |||
| ≤10 | 34 (44.7) | 23 (43.4) | .795 |
| >10 | 11 (14.5) | 9 (17.0) | |
| Missing | 31 (40.8) | 21 (39.6) | |
| BMI, kg/m2 | 24.8 (22.6-27.4) | 25.3 (22.3-28.0) | .843 |
| Comorbidities | |||
| Hypertension∗ | 25 (32.9) | 38 (71.7) | <.001 |
| Type 2 diabetes | 3 (4) | 10 (18.9) | .007 |
| Thromboembolic event† | 19 (25) | 27 (50.9) | .003 |
| Statin treatment | |||
| Moderate intensity‡ | 33 (62.3) | <.001 | |
| High intensity§ | 20 (37.7) | ||
| Cytoreductive treatment | |||
| HU | 23 (30.3) | 23 (43.4) | .139 |
| Pegylated IFN-α2 | 53 (69.7) | 30 (56.6) | |
| Laboratory test | |||
| Hemoglobin, g/dL | 16.0 (14.2-18.5) | 15.3 (13.7-17.2) | .229 |
| Erythrocytes, ×1012/L | 5.6 (4.8-6.8) | 5.2 (4.6-6.0) | .074 |
| WBC, ×109/L | 9.8 (7.5-10.5) | 10.1 (8.2-12.8) | .521 |
| Platelets, ×109/L | 680 (451-888) | 596 (516-753) | .405 |
| JAK2V617F, % | 34.0 (11.8-46.8) | 34.1 (18.0-49.5) | .719 |
| Total cholesterol, mmol/L | 4.9 (4.4-5.7) | 4.0 (3.4-4.5) | <.001 |
| LDL-C, mmol/L | 2.9 (2.4-3.3) | 1.8 (1.6-2.3) | <.001 |
Data are presented as n (%) or median (IQR).
BMI, body mass index; WBC, white blood cell.
Defined by usage of antihypertensive drugs.
Thromboembolic events prior to diagnosis recorded; Cerebral infarct, acute myocardial infarct (STEMI and NSTEMI), deep venous thrombosis, pulmonary embolism, transient ischemic attack and amaurosis fugax.
Includes atorvastatin 10-20 mg, simvastatin 20-40 mg, and rosuvastatin 5-10 mg.
Includes atorvastatin 40-80 mg.